Potential and Emerging Treatment Options for Ebola Virus Disease

Objective: To describe the current Ebola virus epidemic and the potential options for treatment and prevention of Ebola virus disease. Data Sources: A PubMed literature search (1976 through October 20, 2014) was conducted using the search term Ebola. Study Selection and Data Extraction: Animal and human studies published in English were selected. Studies published within the past 5 years were the primary focus of this review. Data Synthesis: The current Ebola virus epidemic has primarily been contained in West Africa though it has subsequently spread to other areas, including the United States. The first patient in the United States infected with Ebola virus was diagnosed, treated, and expired in Texas. Two nurses caring for this patient also were diagnosed with Ebola virus and have been successfully treated. Treatment options for patients infected with Ebola virus are limited. Supportive therapy is centered on fluid resuscitation, electrolyte imbalance correction, treating complicating infections, and preventing complications of shock. Experimental therapies (ZMapp, brincidofovir, TKM-Ebola, and favipiravir) have been used during this current outbreak. Several medications such as amiodarone, chloroquine, and clomiphene may prevent the transmission of or treat Ebola virus. Different vaccine therapies are also in early-stage development. One of the vaccine strategies using recombinant vesicular stomatitis virus as a delivery vector has demonstrated efficacy when used for preexposure and postexposure prophylaxis. Conclusion: Ebola virus is highly virulent and fatal, and treatment options are limited. Several experimental and existing therapies may be options for preventing and treating Ebola virus disease.

[1]  G. Painter,et al.  Development of CMX001 for the Treatment of Poxvirus Infections , 2010, Viruses.

[2]  G. Painter,et al.  First Pharmacokinetic and Safety Study in Humans of the Novel Lipid Antiviral Conjugate CMX001, a Broad-Spectrum Oral Drug Active against Double-Stranded DNA Viruses , 2012, Antimicrobial Agents and Chemotherapy.

[3]  Joshua C. Johnson,et al.  Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study , 2010, The Lancet.

[4]  M. Bray.  Pathogenesis of viral hemorrhagic fever. , 2005, Current opinion in immunology.

[5]  Steven J M Jones,et al.  Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. , 2008, Vaccine.

[6]  P. Jahrling,et al.  Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. , 2003, The American journal of pathology.

[7]  Joshua C. Johnson,et al.  Therapeutic Intervention of Ebola Virus Infection in Rhesus Macaques with the MB-003 Monoclonal Antibody Cocktail , 2013, Science Translational Medicine.

[8]  W. Team.  Ebola Virus Disease in West Africa — The First 9 Months of the Epidemic and Forward Projections , 2014 .

[9]  J. Strong,et al.  Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp™ , 2014, Nature.

[10]  Gianluca Pegoraro,et al.  Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430 , 2014, Nature.

[11]  Asher Mullard.  Experimental Ebola drugs enter the limelight , 2014, The Lancet.

[12]  J. Dye,et al.  Persistent immune responses after Ebola virus infection. , 2013, The New England journal of medicine.

[13]  L. Fernando,et al.  Effective Post-Exposure Treatment of Ebola Infection , 2007, PLoS pathogens.

[14]  K. Mann,et al.  Anticoagulant effects of statins and their clinical implications , 2013, Thrombosis and Haemostasis.

[15]  Peter B. Jahrling,et al.  Clinical Management of Filovirus-Infected Patients , 2012, Viruses.

[16]  I. D. Manger,et al.  A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat Agents , 2013, PloS one.

[17]  Heinz Feldmann,et al.  Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses , 2005, Nature Medicine.

[18]  P. Rollin,et al.  Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. , 1999, The Journal of infectious diseases.

[19]  J. Farrar,et al.  A Randomized Controlled Trial of Chloroquine for the Treatment of Dengue in Vietnamese Adults , 2010, PLoS neglected tropical diseases.

[20]  N. Nomura,et al.  Mechanism of Action of T-705 Ribosyl Triphosphate against Influenza Virus RNA Polymerase , 2013, Antimicrobial Agents and Chemotherapy.

[21]  Heinz Feldmann,et al.  Single-Injection Vaccine Protects Nonhuman Primates against Infection with Marburg Virus and Three Species of Ebola Virus , 2009, Journal of Virology.

[22]  Kathryn L. Schornberg,et al.  FDA-Approved Selective Estrogen Receptor Modulators Inhibit Ebola Virus Infection , 2013, Science Translational Medicine.

[23]  B. Ribner.  Treating Patients with Ebola Virus Infection in the U.S.: Lessons Learned , 2014 .

[24]  D. Musher,et al.  Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  Mario Roederer,et al.  Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge , 2014, Nature Medicine.

[26]  P. Iversen,et al.  Safety and Pharmacokinetic Profiles of Phosphorodiamidate Morpholino Oligomers with Activity against Ebola Virus and Marburg Virus: Results of Two Single-Ascending-Dose Studies , 2014, Antimicrobial Agents and Chemotherapy.

[27]  R. Colebunders,et al.  Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. , 1999, The Journal of infectious diseases.

[28]  S. Günther,et al.  Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. , 2014, Antiviral research.

[29]  H. Feldmann,et al.  Ebola haemorrhagic fever , 2011, The Lancet.

[30]  T. Fletcher,et al.  Caring for critically ill patients with ebola virus disease. Perspectives from West Africa. , 2014, American journal of respiratory and critical care medicine.

[31]  Mikiko Senga,et al.  Ebola virus disease in West Africa--the first 9 months of the epidemic and forward projections. , 2014, The New England journal of medicine.

[32]  Michael McCarthy,et al.  US signs contract with ZMapp maker to accelerate development of the Ebola drug , 2014, BMJ : British Medical Journal.

[33]  R. Peeling,et al.  Lovastatin for adult patients with dengue: protocol for a randomised controlled trial , 2012, Trials.

[34]  D. Smee,et al.  Treatment of Late Stage Disease in a Model of Arenaviral Hemorrhagic Fever: T-705 Efficacy and Reduced Toxicity Suggests an Alternative to Ribavirin , 2008, PloS one.

[35]  A. Flahault,et al.  On chikungunya acute infection and chloroquine treatment. , 2008, Vector borne and zoonotic diseases.

[36]  J. Sagripanti,et al.  Persistence in darkness of virulent alphaviruses, Ebola virus, and Lassa virus deposited on solid surfaces , 2010, Archives of Virology.

[37]  H. Feldmann,et al.  Antiviral Efficacy of Favipiravir against Two Prominent Etiological Agents of Hantavirus Pulmonary Syndrome , 2013, Antimicrobial Agents and Chemotherapy.

[38]  Shu-guang Zhang,et al.  Effect of statin therapy on mortality from infection and sepsis: a meta-analysis of randomized and observational studies , 2014, Critical Care.

[39]  M. Mendenhall,et al.  In Vitro and In Vivo Activities of T-705 against Arenavirus and Bunyavirus Infections , 2007, Antimicrobial Agents and Chemotherapy.

[40]  M. McCarthy.  FDA allows second experimental drug to be tested in Ebola patients , 2014, BMJ : British Medical Journal.

[41]  M. Martínez-Gutiérrez,et al.  Statins Reduce Dengue Virus Production via Decreased Virion Assembly , 2011, Intervirology.

[42]  X. Qiu,et al.  Mucosal Immunization of Cynomolgus Macaques with the VSVΔG/ZEBOVGP Vaccine Stimulates Strong Ebola GP-Specific Immune Responses , 2009, PloS one.

[43]  J. Allain,et al.  Ebola: a call for blood transfusion strategy in sub-Saharan Africa , 2014, The Lancet.

[44]  G. Papanicolaou,et al.  CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. , 2013, The New England journal of medicine.

[45]  D. Fedson.  A practical treatment for patients with Ebola virus disease. , 2015, The Journal of infectious diseases.

[46]  Wei Xu,et al.  Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1. , 2014, Cell host & microbe.

[47]  R. Lenk,et al.  Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. , 2014, Antiviral research.

[48]  H. Feldmann,et al.  Vesicular Stomatitis Virus–Based Vaccines against Lassa and Ebola Viruses , 2015, Emerging infectious diseases.

[49]  S. Kuo,et al.  Effect of the use of low and high potency statins and sepsis outcomes , 2014, Intensive Care Medicine.

[50]  J. Enders,et al.  Infectious Diseases Society of America. , 1969, Antimicrobial agents and chemotherapy.

[51]  Phillip B. Iverson,et al.  Ebola Hemorrhagic Fever , 1997 .

[52]  P. Iversen,et al.  Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections , 2012, Viruses.

[53]  A. Zangrillo,et al.  The Effect of Statins on Mortality in Septic Patients: A Meta-Analysis of Randomized Controlled Trials , 2013, PloS one.

[54]  G. Perkins,et al.  Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial) , 2012, Critical Care.

[55]  M. Manns,et al.  The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry , 2014, The Journal of antimicrobial chemotherapy.

[56]  S. Smither,et al.  The survival of filoviruses in liquids, on solid substrates and in a dynamic aerosol , 2010, Journal of applied microbiology.

[57]  A. Gulland.  First Ebola treatment is approved by WHO , 2014, BMJ : British Medical Journal.

[58]  Kathryn L. Schornberg,et al.  A new player in the puzzle of filovirus entry , 2012, Nature Reviews Microbiology.

[59]  Christopher Dye,et al.  Ebola vaccine--an urgent international priority. , 2014, The New England journal of medicine.